Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanhui Cai

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Human Gene Therapy|June 6, 2018
DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara VaccinationXintao Hu, Antonio Valentin, Yanhui Cai, et al.
Frontiers in Immunology|April 9, 2025
AI discovery of TLR agonist-driven phenotypes reveals unique features of peripheral cells from healthy donors and ART-suppressed people living with HIVRobert Were Omange, Samuel C Kim, Nikita S Kolhatkar, et al.
Infectious Diseases and Therapy|September 15, 2025
The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIVYanan Zheng, Mary Wire, Robert Were Omange, et al.
Infectious Diseases and Therapy|September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist VesatolimodSharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
International Journal of Geriatric Psychiatry|March 14, 2025
Norms of Hong Kong Brief Cognitive Test and the Utility for Screening Cognitive Impairment Among Chinese Older AdultsYaonan Zheng, Jiahui Zhu, Nan Li, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Nature Communications|March 4, 2025
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trialLucia Bailón, José Moltó, Adrian Curran, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Human Gene Therapy|June 6, 2018
DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara VaccinationXintao Hu, Antonio Valentin, Yanhui Cai, et al.
Frontiers in Immunology|April 9, 2025
AI discovery of TLR agonist-driven phenotypes reveals unique features of peripheral cells from healthy donors and ART-suppressed people living with HIVRobert Were Omange, Samuel C Kim, Nikita S Kolhatkar, et al.
Infectious Diseases and Therapy|September 15, 2025
The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIVYanan Zheng, Mary Wire, Robert Were Omange, et al.
Infectious Diseases and Therapy|September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist VesatolimodSharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
International Journal of Geriatric Psychiatry|March 14, 2025
Norms of Hong Kong Brief Cognitive Test and the Utility for Screening Cognitive Impairment Among Chinese Older AdultsYaonan Zheng, Jiahui Zhu, Nan Li, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Nature Communications|March 4, 2025
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trialLucia Bailón, José Moltó, Adrian Curran, et al.
Pageof 5